Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.
F. Stephen Hodi(Harvard University), Jedd D. Wolchok(Cornell University), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Patrick Chun(University of Michigan), Adil Daud(University of California, San Francisco), Andrea Perrone(Università Cattolica del Sacro Cuore), Roxana Dronca(Dana-Farber Cancer Institute), Omid Hamid(Cedars-Sinai Medical Center), Jeffrey S. Weber(NYU Langone Health), Peter Hersey(The University of Sydney), Richard Kefford(Broad Institute), Antoni Ribas(University of California, Los Angeles), Anthony M. Joshua(St Vincent's Hospital Sydney), Caroline Robert(Institut Gustave Roussy), Wen‐Jen Hwu(The University of Texas MD Anderson Cancer Center), Tara C. Gangadhar(University of Pennsylvania), Soonmo Peter Kang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Darcy A. Hille(Merck & Co., Inc., Rahway, NJ, USA (United States)), Dahai Xue(Dana-Farber Cancer Institute), Linda Gammage(United States Military Academy)
Cited by 40
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k